Diabetes mellitus and COVID-19: A review and management guidance for South Africa by Coetzee, A et al.
REVIEW
761       August 2020, Vol. 110, No. 8
Diabetes mellitus (DM), cancer, cardiovascular diseases and chronic 
respiratory diseases, collectively referred to as non-communicable 
diseases (NCDs), are the leading causes of mortality worldwide. DM 
is a major driving force behind the escalating prevalence of NCDs 
and the increasing mortality and morbidity attributable to them, 
especially in lower- and middle-income regions. A predisposition to 
development and poor outcome of infectious diseases in the presence 
of NCDs has been noted and explains the association between DM 
and both tuberculosis (TB) and HIV infection.[1,2] DM places an 
enormous burden on health budgets and health systems globally. This 
is especially concerning in South Africa (SA), where the healthcare 
system is not only overwhelmed by the escalating prevalence of DM, 
but carries an additional burden of disease due to TB and HIV.
The COVID-19 pandemic is infamous for crippling healthcare 
systems. Environments with limited resources are particularly 
vulnerable.[3] The mismatch between healthcare demand and supply 
in SA predates the COVID-19 pandemic.[4] With the expected 
widespread community transmission of SARS-CoV-2 infection in 
SA, preparedness will depend on the implementation of equitable 
and effective strategies derived from the experiences of countries 
that are up front in the COVID-19 fight.[5-7] Increased morbidity and 
mortality from COVID-19 in patients with DM have been noted in 
countries hardest hit by the pandemic, and this association and the 
optimal management of infected patients with DM deserve close 
scrutiny.
DM is one of the leading causes of morbidity and mortality 
worldwide, mostly attributed to cardiovascular disease (CVD). [8] 
Globally, DM and obesity accounted for 43.4% of all deaths in 
2012, compared with 33.6% of deaths from HIV/AIDS and TB 
combined. [8,9] In SA, high body mass indexes (BMIs) and DM are the 
second and third  leading risk factors for early death and disability, 
respectively, and the increasing overlap with infectious diseases is 
a growing concern.[10-12] When the co-presence of COVID-19 and 
NCDs was investigated in Italy, hypertension and DM were identified 
as the two most prevalent comorbidities with rates of 73.8% and 
33.9%, respectively, DM being three times more prevalent in patients 
with severe COVID-19 than in the background population. [13] 
In 2019, the International Diabetes Federation reported a DM 
prevalence of 12.8% in SA adults (20 - 79 years), but cautioned 
that this may be an underestimate, as DM in Africa remains largely 
undiagnosed (3/5 persons with DM; 60%).[14] Based on available 
evidence from China and Italy, people living with diabetes (PLWD) 
do not have an increased risk of being infected with SARS-CoV-2, 
as the prevalence of COVID-19 in PLWD was similar to that of the 
background population in these geographical areas.[15,16]
Assessment of the impact of the convergence of these two diseases 
in SA will be challenging. Many PLWD remain undiagnosed in 
this country, limiting the ability to truly estimate the background 
prevalence of DM. There are also people with SARS-CoV-2 infection 
who remain asymptomatic. There are theoretical reasons why PLWD 
may be at increased risk of acquiring SARS-CoV-2 infection and 
potentially have a more severe and complicated disease course. 
In general, PLWD are at increased risk of infections due to an 
impaired immune response with reductions in cytokines, T-cell 
activation, neutrophil function and macrophage activity.[17,18] DM 
is also a chronic inflammatory condition that in itself is associated 
with adverse outcomes.[19] The vast majority of patients in our setting 
with type 2 DM (T2DM) are obese, and obesity was identified as an 
independent risk factor for severe infection during the influenza A 
H1N1 epidemic in 2009.[20] Obesity is associated with respiratory 
problems that include reduced ventilation of basal lung segments, 
ventilation-perfusion mismatches and suboptimal blood oxygenation, 
all of which can potentially contribute to the complexities involved in 
managing PLWD who have COVID-19.[21]
DM and coronaviruses
DM was a risk factor for severe disease and excess mortality in severe 
acute respiratory syndrome (SARS) and Middle East respiratory 
syndrome (MERS), and the associated viruses were found to be an 
aetiological factor in the development of DM by damaging pancreatic 
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islet cells.[22-25] Based on the experience with SARS and MERS, 
it is anticipated that DM will predispose to increased severity of 
COVID-19. Infection with SARS-CoV-2 may also adversely affect 
endocrine pancreatic function and worsen glycaemic control. The 
reported prevalence of DM in people with COVID-19 varies and is 
influenced by geographical area, age of the population and severity 
of disease. A meta-analysis of 12 studies that included 2 108 Chinese 
patients with COVID-19 noted a DM prevalence of 10.3%, a figure 
not dissimilar to the known prevalence of diabetes in the background 
general population.[15] However, the disease was notably more severe 
and the mortality rate higher in PLWD in China. This finding is 
supported by a report by Yang et al.,[26] who showed the prevalence 
of DM in patients requiring intensive care unit (ICU) admission 
for severe COVID-19 to be as high as 22%. Studies from China 
documented an overall mortality rate of 2.3%, compared with a three 
times higher mortality rate of 7.3% in PLWD.[27,28] Similarly, in Italy, 
Grasselli et al.[29] reported a high prevalence of DM (17%) in 1 591 
patients infected with SARS-CoV-2 who required ICU admission. 
The reported prevalence in Italy increased even further to a very 
concerning 35.5% of PLWD who had a fatal outcome following ICU 
admission.[30] In a case series of 5 700 hospitalised patients in the New 
York City area, the most common comorbidities were hypertension 
(n=3 026; 56.6%), obesity (n=1 737; 41.7%) and DM (n=1 808; 
33.8%).[31] Compared with patients without DM, PLWD had a more 
protracted illness, there was a longer period of viral shedding, the 
requirement for mechanical ventilation increased, and more deaths 
were reported.[32]
Effect of abnormal glucose on 
outcome with COVID-19
Hyperglycaemia is a robust predictor of severity of illness and 
mortality in patients infected with various viruses, including influenza 
A (H1N1), SARS and MERS, in part owing to the catecholamine 
response associated with systemic infections.[22-24] Poorly controlled 
DM and chronic hyperglycaemia are linked to defects in lymphocyte 
proliferation as well as impaired monocyte/macrophage and 
neutrophil function.[17] Furthermore, hyperglycaemia in the 
pulmonary vasculature at the time of infection has been shown to 
increase local influenza viral replication  in lung tissue.[33] Poor DM 
control is therefore expected to predispose to infection and a more 
adverse outcome with increased complications in persons exposed 
to the SARS-CoV-2 virus. DM and/or uncontrolled hyperglycaemia 
(defined as two or more blood glucose levels >10 mmol/L/24 h) in 
1 122 hospitalised patients was associated with increased mortality 
and a longer hospital stay in an observational study in the USA.[34] In 
the same study, a mortality rate of 28.8% was noted in patients with 
uncontrolled hyperglycaemia (with or without known DM; n=570) 
compared with 6.2% mortality in the absence of these comorbidities. 
Among the 184 patients with known DM, 40 of 96 (41.7%) with 
uncontrolled hyperglycaemia died, compared with 13 of 88 (14.8%) 
patients with DM that was controlled.[34] An analysis of COVID-19-
related hospital deaths in the linked electronic health records of over 
17 million adult National Health Service patients showed increasing 
BMI, DM and poorly controlled DM to be associated with increased 
mortality.[35]
Glycated haemoglobin (HbA1c) reflects mean glucose status for 
the preceding 12 weeks. It does not replace glucose monitoring in the 
acutely ill, but is a reliable indicator of the glycaemic environment 
prior to the onset of an illness or disease process.[36] Measured HbA1c 
has been validated for case finding for DM in hospitalised patients.[37] 
HbA1c-based score models have been used to predict cardiovascular 
outcome and mortality in PLWD and may prove to be a useful 
aid in defining risk and allocating resources in PLWD who have 
COVID-19.
Conversely, a retrospective study from Wuhan reported that ~10% 
of patients with T2DM and SARS-CoV-2 infection experienced at least 
one episode of hypoglycaemia (<3.9 mmol/L).[38] Since hypoglycaemia 
is a predictor of an adverse outcome, partly attributable to a robust 
inflammatory response with consequences such as hypercoagulability 
and cardiac arrhythmias, it would also be important to avoid it when 
managing PLWD who are infected with SARS-CoV-2.
Obesity is causally related to hypertension, T2DM and cardio-
vascular diseases, and was also associated with adverse outcome during 
the H1N1 pandemic.[39] A retrospective study from France indicated 
that the odds ratio for mechanical ventilation in COVID-19 patients 
categorised as severely obese (BMI >35 kg/m2) was 7.36 (p=0.02) 
compared with individuals with a BMI in the normal weight category 
(<25 kg/m2).[40] Multivariate analysis confirmed the association to 
be independent of age, T2DM status and hypertension. [40] Restricted 
pulmonary function, immunological aberrations including raised 
interleukin-6 and other pro-inflammatory cytokines, chronic low-
grade inflammation and hypercoagulability are all implicated as 
potential contributors to the adverse outcome in the obese.[39] The 
level of human angiotensin-converting enzyme 2 (ACE2) receptor 
expression in adipose tissue is higher than in lung tissue, and obese 
individuals consequently have a larger total amount of ACE2.[41] While 
obesity and DM are intricately linked and both are associated with 
more severe COVID-19, glucose control is generally achievable in a 
shorter time period than weight loss. Well-controlled blood glucose 
was correlated with improved 28-day outcomes following admission 
for COVID-19 in individuals with T2DM and the in-hospital death 
rate was reduced ten-fold (1.1% v. 11%) compared with individuals 
with uncontrolled blood glucose.[42]
Management of PLWD without 
current COVID-19
Poor glycaemic control in DM is associated with more severe 
infectious disease, including pneumonia and other bacterial 
infections.[43] In vitro  exposure of pulmonary epithelial cells to 
elevated glucose concentrations significantly increased influenza 
virus infection and replication in a dose-response fashion, suggesting 
that hyperglycaemia may increase viral replication.[33] Higher HbA1c 
values (>7.5%) reflecting suboptimal glucose control before COVID-
19 were associated with an increased risk (adjusted hazard ratio 
(AHR) 2.36; 95% confidence interval (CI) 2.18 - 2.56) of in-hospital 
deaths in England compared with HbA1c values <7.5% (AHR 1.5; 
95% CI 1.40 - 1.60).[35] It is therefore advised that glucose control 
should be prioritised according to best practice guidelines. This is 
applicable to all PLWD with COVID-19.
Chronic management of DM and  
mild COVID-19
It is important that PLWD minimise their risk by being proactive with 
regard to both prevention strategies for SARS-CoV-2 infection and 
the control of comorbid medical conditions. The majority of PLWD 
with COVID-19 are likely to have mild disease that can be managed 
at home, provided they can adhere to public health measures and self-
manage glycaemia. PLWD with mild COVID-19 who are recovering 
at home should consult their healthcare providers on effective blood 
glucose management. It is therefore important that clinicians caring 
for PLWD familiarise themselves with pharmacotherapy frequently 
used in PLWD and COVID-19. The disease course of patients with 
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COVID-19 and DM is highly variable. It is therefore advised that 
the management plan, including use of glucose-lowering agents, is 
revisited with any change in clinical condition.
Angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers
While outcomes remain to be clarified in SARS-CoV-2 infection, 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers (ARBs) have been shown to improve outcome 
in various subpopulations of PLWD.[44-46] The pathophysiological 
basis of concern regarding using ACE inhibitors in people infected 
with SARS-CoV-2 lies in the binding of SARS-CoV-2 to the ACE2 
receptor, thereby gaining entry into target cells.[47] Under normal 
physiological conditions, ACE2 is expressed in the pulmonary 
epithelium, vasculature and intestine, and is upregulated in patients 
treated with ACE inhibitors and ARBs. It has therefore been 
suggested that increased ACE2 expression in PLWD could facilitate 
infection and increase severity.[48] While association does not prove 
causality, it is interesting to note that ACE inhibitor and ARB use 
in patients with hypertension admitted with SARS-CoV-2 infection 
in China were not associated with adverse outcomes.[49] At this time 
there are insufficient data to inform the clinician on whether these 
agents should or should not be used in PLWD who have COVID-
19. However, there could potentially be more harm in stopping 
these agents, especially in patients with mild COVID-19 disease 
and concomitant hypertension, renal disease, heart failure and 
cardiovascular disease. Many societies, including the International 
Society of Hypertension and the European Society of Hypertension, 
are in agreement that, based on available evidence, ACE inhibitors 
and ARBs should not be discontinued in people with COVID-19.[50,51]
Oral glucose-lowering agents
From an oral glucose-lowering perspective, metformin is a commonly 
used agent, and usually the foundation of the treatment cascade 
for managing patients with T2DM. Metformin has been shown 
to have anti-inflammatory properties, albeit with questionable 
clinical relevance, and can safely be continued in PLWD with 
mild concomitant COVID-19.[52] However, the risk/benefit ratio 
in individuals with severe illness favours discontinuation.[53] 
A  dipeptidyl peptidase-IV (DPPIV) enzyme inhibitor is often used 
in the management of patients with T2DM. The DPPIV enzyme 
has been localised to type 1 and type 2 pneumocytes and has 
been shown to be increased in smoking and chronic lung disease 
and decreased in people with HIV and MERS.[54] The membrane-
associated DPPIV receptor is a functional coronavirus receptor, and 
anti-DPPIV antibodies have been shown to decrease susceptibility 
to coronavirus infection.[55] Similarly, decreased expression of 
cell-surface DPPIV correlates with reduced disease susceptibility, 
suggesting that DPPIV inhibitors may have pathophysiological 
significance; however, genetic polymorphisms, adequate plasma 
levels and concomitant renal function in SARS-CoV-2 infection 
are among the undefined variables that remain to be resolved.[54] 
Glucagon-like peptide-1 (GLP-1) receptor agonists have been shown 
to have anti-inflammatory activity, and some in vitro data show a 
reduction in pulmonary inflammation and cytokine reduction.[54] 
However, there are no data on their safety and efficacy in PLWD 
who have COVID-19. The same is true for sulfonylureas and sodium 
glucose transport 2 (SGLT2) inhibitors. Acute kidney injury can 
develop at any time during COVID-19, and this should be considered 
when antihyperglycaemic agents are prescribed. Kidney injury may 
be due to indirect causes such as volume depletion, direct injury due 
to glomerular or tubular infection with SARS-CoV-2, thrombosis and 
rhabdomyolysis.[56] The safety of many antihyperglycaemic drugs is 
compromised in the presence of renal impairment, albeit to a varying 
extent. As glomerular filtration rate (GFR) cut-offs differ between 
and within antihyperglycaemic classes and agents, it is advised that 
prescribers familiarise themselves with the GFR cut-offs of the 
specific therapeutic agent and/or drug class used. Since COVID-
19 has a wide spectrum of disease severity, the treating clinician 
will have to optimise glycaemic control using clinical judgement as 
well as obeying the standard contraindications for each drug class. 
Prescriber safety considerations for the use of antihyperglycaemic 
agents in PLWD with COVID-19 are addressed in Table 1.
In-hospital management of DM and 
SARS-CoV-2 infection
There are currently no robust data from randomised controlled 
trials detailing the optimal in-hospital care of patients with DM 
and SARS-CoV-2 infection. Observational studies emerging from 
areas of the world that have large numbers of patients with diabetes 
admitted with SARS-CoV-2 infection report a more complicated 
clinical course and a worse outcome in patients with DM, especially 
if the diabetes is poorly controlled. Furthermore, non-diabetic 
patients with hyperglycaemia have higher mortality than those with 
normoglycaemia.[34] These studies also suggest a high prevalence of 
diabetic ketoacidosis (DKA), which is not unexpected in patients 
with infection, but what seems to be unique is that the DKA 
is occurring at or slightly above normal glucose values.[61] The 
contribution of ketosis due to anorexia and a metabolic acidosis 
due to severe dehydration and sepsis is difficult to dissect out 
from the presentation of DKA at this time.[62] Data indicating that 
optimal control of glycaemia in PLWD before and during admission 
with SARS-CoV-2 infection improves outcome are emerging.[34,35,43] 
Clinicians must attempt to optimise blood glucose control in these 
patients while limiting the risk of hypoglycaemia and weight 
gain. Since many of these patients are admitted with anorexia and 
clinical signs of dehydration and infection, the optimal method of 
control in these patients would be administration of subcutaneous 
or intravenous insulin, depending on the clinical status of the 
patient and resources. Considering the infection risk, it would be 
best to limit exposure of healthcare workers by empowering PLWD 
with SARS-CoV-2 infection to perform self-monitoring of blood 
glucose and self-administer insulin if clinical status permits. The 
ongoing use of oral medication depends on the clinical status of 
the patient, the expected adverse effects of the specific agent, and 
glucose readings. It would be preferable to discontinue agents with 
an added risk of hypoglycaemia, dehydration and acidosis in PLWD 
and severe SARS-CoV-2 infection. Additionally, clinical vigilance 
should prevail with regard to variation in renal function, use of 
radiographic contrast agents, and factors increasing the likelihood 
of a suboptimal outcome. Furthermore, clinicians may encounter 
PLWD who receive therapeutic agents directed at SARS-CoV-2 that 
affect glucose levels per se, requiring an adjustment of antidiabetic 
medication. The drugs directed at SARS-CoV-2 that are expected 
to alter glucose levels include the immunomodulators and antiviral 
agents. From an immunomodulatory perspective, chloroquine/
hydroxychloroquine and glucocorticoids have opposing effects on 
blood glucose, with an increased risk of hypo- and hyperglycaemia, 
respectively. The antiviral agent lopinavir/ritonavir is associated with 
hyperglycaemia. Drug-drug interactions such as the concomitant 
use of statins and the antiviral agents lopinavir/ritonavir and 
remdesivir should also be carefully considered.
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Table 1. Prescriber safety considerations and practice suggestions for commonly used antihyperglycaemic drugs in DM with 
concurrent SARS-CoV-2 infection
Prescriber safety considerations
                  Practice suggestions with SARS-CoV-2 infection
Mild disease* Severe disease*
Oral antihyperglycaemic agents
Biguanides
Metformin • Low risk of hypoglycaemia
• Risk of lactic acidosis
No concern Discontinue if severe disease, 
renal impairment (GFR 
<30 mL/min)[57] or circulatory 
insufficiency
DPPIV inhibitors • Low risk of hypoglycaemia
• Theoretically may help offset 
cytokine-related complications
No concern Consider renal functional 
abnormalities for the 
individual agent
Thiazolidinediones
Pioglitazone • Low risk of hypoglycaemia
• Risk of fluid retention
• Theoretical risk of upregulation of 
ACE2 in rats, no human studies[59]
Minimal clinical concern. Potential 
beneficial role based on animal studies 
only[60]
Discuss with endocrinologist 
or diabetologist specialist 
physician
Sulfonylureas • Risk of hypoglycaemia May be continued if renal function 
allows, provided eating, hydration and 
patient self-care are unaffected
Discontinue if severe 
disease, renal impairment or 
circulatory insufficiency
SGLT2 inhibitors • Low risk of hypoglycaemia
• Risk of euglycaemic diabetic 
ketoacidosis
• Risk of dehydration
May be continued if renal function 
allows, provided eating, hydration and 
patient self-care, with specific reference 
to personal hygiene, unaffected†
Discontinue (pending results 
of the DARE-19 trial[58])
Injectable antihyperglycaemic agents
GLP-1 receptor agonists
Liraglutide
Exenatide
Dulaglutide
• Low risk of hypoglycaemia
• Theoretical risk with promotion of 
human ACE2 activity
• Delay in gastric emptying
May be continued provided eating 
hydration and self-care unaffected
Discontinue
Insulin • Risk of hypoglycaemia
• Requires frequent monitoring and 
dose adjustments
• Sole therapy for people with T1DM
May be continued, but frequent 
adjustment required based on glucose 
readings, caloric intake, meals and safety 
of self-administration 
• Refer to SEMDSA 
guidelines (in-hospital 
management of 
hyperglycaemia)[57]
• Insulin is the drug of choice 
in the critically ill
• Specific regimen will 
depend on setting (medical 
ward v. ICU)
Basal • Consider the risk of hypoglycaemia Continue, but consider dose adjustment.
Basal insulins with a peak effect may 
require adjustments with reduction in 
appetite
• Continued use supported 
in basal bolus-like regimen 
dependent on setting 
(medical ward v. ICU)
 Prandial/short-acting 
insulin
• Consider the risk of hypoglycaemia May require frequent dose adjustment 
depending on glucose readings, appetite 
and caloric intake, etc. 
• Continued use supported 
with basal bolus-like regimen
• In ICU, intravenous route 
preferred with regular 
titration as per protocol
Premix insulin • Consider the risk of hypoglycaemia Prandial component may not meet 
prandial needs, with risk of hypo/
hyperglycaemia if mismatch due to 
concurrent illness
May be continued if renal function 
allows, provided eating, hydration and 
patient self-care and ability to self-
monitor is unaffected
Basal bolus-like regimen or 
short-acting insulin preferred
DM = diabetes mellitus (T1 = type 1, T2 = type 2); GFR = glomerular filtration rate; DPPIV = dipeptidyl peptidase-IV; ACE2 = angiotensin-converting enzyme 2; SGLT2 = sodium glucose 
transport protein 2; GLP-1 = glucagon-like peptide 1; DARE = Dapagliflozin in Respiratory Failure in Patients With COVID-19; SEMDSA = Society for Endocrinology, Metabolism and Diabetes 
of South Africa; ICU = intensive care unit.
*Mild and severe SARS-CoV-2 disease as defined by the World Health Organization.[59] Diabetes with no concurrent SARS-CoV-2 infection should be managed according to the SEMDSA 
guidelines for the management of T2DM in adults.[57]
†Personal hygiene advice associated with a significant reduction in genital mycotic infection.[60]
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Conclusions
The convergence of the DM epidemic and COVID-19 pandemic will 
significantly increase the demands on the SA healthcare system. The 
available evidence identifies obesity, and hyperglycaemia in patients 
without diabetes, as well as poorly controlled DM as important 
modifiable host factors associated with adverse outcomes. Clinicians 
should remain vigilant with regard to the glucose fluctuations 
in SARS-CoV-2 infection and address them proactively. HbA1c 
determination at the time of diagnosis of COVID-19 and/or on 
admission may clarify DM status and allow for the early initiation of 
therapies to best manage hyperglycaemia.
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